Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

Glycoengineering HIV-1 Env creates 'supercharged' and 'hybrid' glycans to increase neutralizing antibody potency, breadth and saturation.

Crooks ET, Grimley SL, Cully M, Osawa K, Dekkers G, Saunders K, Rämisch S, Menis S, Schief WR, Doria-Rose N, Haynes B, Murrell B, Cale EM, Pegu A, Mascola JR, Vidarsson G, Binley JM.

PLoS Pathog. 2018 May 2;14(5):e1007024. doi: 10.1371/journal.ppat.1007024. eCollection 2018 May.

2.

Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.

Cale EM, Gorman J, Radakovich NA, Crooks ET, Osawa K, Tong T, Li J, Nagarajan R, Ozorowski G, Ambrozak DR, Asokan M, Bailer RT, Bennici AK, Chen X, Doria-Rose NA, Druz A, Feng Y, Joyce MG, Louder MK, O'Dell S, Oliver C, Pancera M, Connors M, Hope TJ, Kepler TB, Wyatt RT, Ward AB, Georgiev IS, Kwong PD, Mascola JR, Binley JM.

Immunity. 2017 May 16;46(5):777-791.e10. doi: 10.1016/j.immuni.2017.04.011.

3.

Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction.

Crooks ET, Osawa K, Tong T, Grimley SL, Dai YD, Whalen RG, Kulp DW, Menis S, Schief WR, Binley JM.

Virology. 2017 May;505:193-209. doi: 10.1016/j.virol.2017.02.024. Epub 2017 Mar 6.

4.

Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.

Doria-Rose NA, Altae-Tran HR, Roark RS, Schmidt SD, Sutton MS, Louder MK, Chuang GY, Bailer RT, Cortez V, Kong R, McKee K, O'Dell S, Wang F, Abdool Karim SS, Binley JM, Connors M, Haynes BF, Martin MA, Montefiori DC, Morris L, Overbaugh J, Kwong PD, Mascola JR, Georgiev IS.

PLoS Pathog. 2017 Jan 4;13(1):e1006148. doi: 10.1371/journal.ppat.1006148. eCollection 2017 Jan.

5.

HIV-host interactome revealed directly from infected cells.

Luo Y, Jacobs EY, Greco TM, Mohammed KD, Tong T, Keegan S, Binley JM, Cristea IM, Fenyö D, Rout MP, Chait BT, Muesing MA.

Nat Microbiol. 2016 Jul;1(7):16068. Epub 2016 May 23.

6.

Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env.

Kwon YD, Pancera M, Acharya P, Georgiev IS, Crooks ET, Gorman J, Joyce MG, Guttman M, Ma X, Narpala S, Soto C, Terry DS, Yang Y, Zhou T, Ahlsen G, Bailer RT, Chambers M, Chuang GY, Doria-Rose NA, Druz A, Hallen MA, Harned A, Kirys T, Louder MK, O'Dell S, Ofek G, Osawa K, Prabhakaran M, Sastry M, Stewart-Jones GB, Stuckey J, Thomas PV, Tittley T, Williams C, Zhang B, Zhao H, Zhou Z, Donald BR, Lee LK, Zolla-Pazner S, Baxa U, Schön A, Freire E, Shapiro L, Lee KK, Arthos J, Munro JB, Blanchard SC, Mothes W, Binley JM, McDermott AB, Mascola JR, Kwong PD.

Nat Struct Mol Biol. 2015 Jul;22(7):522-31. doi: 10.1038/nsmb.3051. Epub 2015 Jun 22.

7.

Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.

Crooks ET, Tong T, Chakrabarti B, Narayan K, Georgiev IS, Menis S, Huang X, Kulp D, Osawa K, Muranaka J, Stewart-Jones G, Destefano J, O'Dell S, LaBranche C, Robinson JE, Montefiori DC, McKee K, Du SX, Doria-Rose N, Kwong PD, Mascola JR, Zhu P, Schief WR, Wyatt RT, Whalen RG, Binley JM.

PLoS Pathog. 2015 May 29;11(5):e1004932. doi: 10.1371/journal.ppat.1004932. eCollection 2015 May.

8.

Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.

Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Imamichi H, Georgiev IS, Chuang GY, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, de la Peña AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M.

Nature. 2014 Nov 6;515(7525):138-42. doi: 10.1038/nature13601. Epub 2014 Sep 3.

9.

Multi-parameter exploration of HIV-1 virus-like particles as neutralizing antibody immunogens in guinea pigs, rabbits and macaques.

Tong T, Crooks ET, Osawa K, Robinson JE, Barnes M, Apetrei C, Binley JM.

Virology. 2014 May;456-457:55-69. doi: 10.1016/j.virol.2014.03.015. Epub 2014 Mar 29.

10.

Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and Macaques.

Tong T, Crooks ET, Osawa K, Robinson JE, Barnes M, Apetrei C, Binley JM.

Virology. 2014 May;456-457:55-69.

11.

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Doria-Rose NA, Schramm CA, Gorman J, Moore PL, Bhiman JN, DeKosky BJ, Ernandes MJ, Georgiev IS, Kim HJ, Pancera M, Staupe RP, Altae-Tran HR, Bailer RT, Crooks ET, Cupo A, Druz A, Garrett NJ, Hoi KH, Kong R, Louder MK, Longo NS, McKee K, Nonyane M, O'Dell S, Roark RS, Rudicell RS, Schmidt SD, Sheward DJ, Soto C, Wibmer CK, Yang Y, Zhang Z; NISC Comparative Sequencing Program, Mullikin JC, Binley JM, Sanders RW, Wilson IA, Moore JP, Ward AB, Georgiou G, Williamson C, Abdool Karim SS, Morris L, Kwong PD, Shapiro L, Mascola JR.

Nature. 2014 May 1;509(7498):55-62. doi: 10.1038/nature13036. Epub 2014 Mar 2.

12.

A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.

Gach JS, Quendler H, Tong T, Narayan KM, Du SX, Whalen RG, Binley JM, Forthal DN, Poignard P, Zwick MB.

PLoS One. 2013 Aug 26;8(8):e72054. doi: 10.1371/journal.pone.0072054. eCollection 2013.

13.

Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.

Bontjer I, Melchers M, Tong T, van Montfort T, Eggink D, Montefiori D, Olson WC, Moore JP, Binley JM, Berkhout B, Sanders RW.

PLoS One. 2013 Jun 26;8(6):e67484. doi: 10.1371/journal.pone.0067484. Print 2013.

14.

Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120.

Tong T, Osawa K, Robinson JE, Crooks ET, Binley JM.

J Virol. 2013 Aug;87(16):9233-49. doi: 10.1128/JVI.01145-13. Epub 2013 Jun 5.

15.

Inhibition of the HIV-1 spike by single-PG9/16-antibody binding suggests a coordinated-activation model for its three protomeric units.

Löving R, Sjöberg M, Wu SR, Binley JM, Garoff H.

J Virol. 2013 Jun;87(12):7000-7. doi: 10.1128/JVI.00530-13. Epub 2013 Apr 17.

16.

M48U1 CD4 mimetic has a sustained inhibitory effect on cell-associated HIV-1 by attenuating virion infectivity through gp120 shedding.

Selhorst P, Grupping K, Tong T, Crooks ET, Martin L, Vanham G, Binley JM, Ariën KK.

Retrovirology. 2013 Feb 1;10:12. doi: 10.1186/1742-4690-10-12.

17.

Anti-HIV B Cell lines as candidate vaccine biosensors.

Ota T, Doyle-Cooper C, Cooper AB, Huber M, Falkowska E, Doores KJ, Hangartner L, Le K, Sok D, Jardine J, Lifson J, Wu X, Mascola JR, Poignard P, Binley JM, Chakrabarti BK, Schief WR, Wyatt RT, Burton DR, Nemazee D.

J Immunol. 2012 Nov 15;189(10):4816-24. doi: 10.4049/jimmunol.1202165. Epub 2012 Oct 12.

18.

HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Tong T, Crooks ET, Osawa K, Binley JM.

J Virol. 2012 Apr;86(7):3574-87. doi: 10.1128/JVI.06938-11. Epub 2012 Feb 1.

19.

Targeting HIV-1 envelope glycoprotein trimers to B cells by using APRIL improves antibody responses.

Melchers M, Bontjer I, Tong T, Chung NP, Klasse PJ, Eggink D, Montefiori DC, Gentile M, Cerutti A, Olson WC, Berkhout B, Binley JM, Moore JP, Sanders RW.

J Virol. 2012 Mar;86(5):2488-500. doi: 10.1128/JVI.06259-11. Epub 2011 Dec 28.

20.

Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals.

Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, Moore PL, Tumba N, Tong T, Shen X, Yates NL, Decker J, Wibmer CK, Gao F, Alam SM, Easterbrook P, Abdool Karim S, Kamanga G, Crump JA, Cohen M, Shaw GM, Mascola JR, Haynes BF, Montefiori DC, Morris L.

J Virol. 2011 Nov;85(21):11502-19. doi: 10.1128/JVI.05363-11. Epub 2011 Aug 17.

21.

Enzyme digests eliminate nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers intact and viral infectivity unaffected.

Crooks ET, Tong T, Osawa K, Binley JM.

J Virol. 2011 Jun;85(12):5825-39. doi: 10.1128/JVI.00154-11. Epub 2011 Apr 6.

22.

Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization.

Binley JM, Ban YE, Crooks ET, Eggink D, Osawa K, Schief WR, Sanders RW.

J Virol. 2010 Jun;84(11):5637-55. doi: 10.1128/JVI.00105-10. Epub 2010 Mar 24.

23.

Effect of trimerization motifs on quaternary structure, antigenicity, and immunogenicity of a noncleavable HIV-1 gp140 envelope glycoprotein.

Du SX, Idiart RJ, Mariano EB, Chen H, Jiang P, Xu L, Ostrow KM, Wrin T, Phung P, Binley JM, Petropoulos CJ, Ballantyne JA, Whalen RG.

Virology. 2009 Dec 5;395(1):33-44. doi: 10.1016/j.virol.2009.07.042. Epub 2009 Oct 8.

24.

Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.

Gray ES, Madiga MC, Moore PL, Mlisana K, Abdool Karim SS, Binley JM, Shaw GM, Mascola JR, Morris L.

J Virol. 2009 Nov;83(21):11265-74. doi: 10.1128/JVI.01359-09. Epub 2009 Aug 19.

25.

Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1.

Kang YK, Andjelic S, Binley JM, Crooks ET, Franti M, Iyer SP, Donovan GP, Dey AK, Zhu P, Roux KH, Durso RJ, Parsons TF, Maddon PJ, Moore JP, Olson WC.

Vaccine. 2009 Aug 13;27(37):5120-32. doi: 10.1016/j.vaccine.2009.06.037. Epub 2009 Jun 28.

26.

Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors.

Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, Haynes BF, Mascola JR, Morris L.

J Virol. 2009 Sep;83(17):8925-37. doi: 10.1128/JVI.00758-09. Epub 2009 Jun 24.

27.

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR.

J Virol. 2008 Dec;82(23):11651-68. doi: 10.1128/JVI.01762-08. Epub 2008 Sep 24.

28.

Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization.

Crooks ET, Jiang P, Franti M, Wong S, Zwick MB, Hoxie JA, Robinson JE, Moore PL, Binley JM.

Virology. 2008 Aug 1;377(2):364-78. doi: 10.1016/j.virol.2008.04.045. Epub 2008 Jun 9.

29.

A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.

Crooks ET, Moore PL, Franti M, Cayanan CS, Zhu P, Jiang P, de Vries RP, Wiley C, Zharkikh I, Schülke N, Roux KH, Montefiori DC, Burton DR, Binley JM.

Virology. 2007 Sep 30;366(2):245-62. Epub 2007 Jun 19.

30.

An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10.

Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, Hessell A, Wilson IA, Binley JM, Dawson PE, Burton DR, Zwick MB.

J Virol. 2007 Apr;81(8):4033-43. Epub 2007 Feb 7.

31.

Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.

Metzner KJ, Binley JM, Gettie A, Marx P, Nixon DF, Connor RI.

Retrovirology. 2006 Dec 21;3:97.

32.
33.

Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120.

Binley JM, Ngo-Abdalla S, Moore P, Bobardt M, Chatterji U, Gallay P, Burton DR, Wilson IA, Elder JH, de Parseval A.

Retrovirology. 2006 Jul 3;3:39. Erratum in: Retrovirology. 2007;4:23.

34.

Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.

Crooks ET, Moore PL, Richman D, Robinson J, Crooks JA, Franti M, Schülke N, Binley JM.

Hum Antibodies. 2005;14(3-4):101-13.

35.

Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1.

Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, Grise H, Corcoran P, Zwick MB, Franti M, Morris L, Roux KH, Burton DR, Binley JM.

J Virol. 2006 Mar;80(5):2515-28.

36.

Evaluation of CD8+ T-cell and antibody responses following transient increased viraemia in rhesus macaques infected with live, attenuated simian immunodeficiency virus.

Metzner KJ, Moretto WJ, Donahoe SM, Jin X, Gettie A, Montefiori DC, Marx PA, Binley JM, Nixon DF, Connor RI.

J Gen Virol. 2005 Dec;86(Pt 12):3375-84.

PMID:
16298985
37.

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41.

Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson IA.

Immunity. 2005 Feb;22(2):163-73.

38.

Vaccination with an inactivated virulent feline immunodeficiency virus engineered to express high levels of Env.

Hosie MJ, Klein D, Binley JM, Dunsford TH, Jarrett O, Neil JC, Knapp E, Giannecchini S, Matteucci D, Bendinelli M, Hoxie JA, Willett BJ.

J Virol. 2005 Feb;79(3):1954-7.

39.

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR.

J Virol. 2004 Dec;78(23):13232-52.

40.

Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions.

Binley JM, Cayanan CS, Wiley C, Schülke N, Olson WC, Burton DR.

J Virol. 2003 May;77(10):5678-84.

41.

Oligomeric and conformational properties of a proteolytically mature, disulfide-stabilized human immunodeficiency virus type 1 gp140 envelope glycoprotein.

Schülke N, Vesanen MS, Sanders RW, Zhu P, Lu M, Anselma DJ, Villa AR, Parren PW, Binley JM, Roux KH, Maddon PJ, Moore JP, Olson WC.

J Virol. 2002 Aug;76(15):7760-76.

42.

Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.

Moulard M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, Zhang MY, Sidorov IA, Broder CC, Robinson J, Parren PW, Burton DR, Dimitrov DS.

Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8. Epub 2002 May 7.

43.

Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.

Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, Schiffner L, Travis B, Kuhmann S, Burton DR, Hu SL, Olson WC, Moore JP.

J Virol. 2002 Mar;76(6):2606-16.

44.

Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5.

Parker CE, Deterding LJ, Hager-Braun C, Binley JM, Schülke N, Katinger H, Moore JP, Tomer KB.

J Virol. 2001 Nov;75(22):10906-11.

45.

Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW.

J Virol. 2001 Nov;75(22):10892-905.

46.

The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.

Binley JM, Trkola A, Ketas T, Schiller D, Clas B, Little S, Richman D, Hurley A, Markowitz M, Moore JP.

J Infect Dis. 2000 Sep;182(3):945-9. Epub 2000 Aug 1.

PMID:
10950795
47.
48.

Passive infusion of immune serum into simian immunodeficiency virus-infected rhesus macaques undergoing a rapid disease course has minimal effect on plasma viremia.

Binley JM, Clas B, Gettie A, Vesanen M, Montefiori DC, Sawyer L, Booth J, Lewis M, Marx PA, Bonhoeffer S, Moore JP.

Virology. 2000 Apr 25;270(1):237-49.

49.

The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy.

Binley JM, Schiller DS, Ortiz GM, Hurley A, Nixon DF, Markowitz MM, Moore JP.

J Infect Dis. 2000 Apr;181(4):1249-63. Epub 2000 Apr 13.

PMID:
10762561
50.

Parameters influencing measurement of the Gag antigen-specific T-proliferative response to HIV type 1 infection.

Schiller DS, Binley JM, Roux KH, Adamson CS, Jones IM, Krausslich HG, Hurley A, Markowitz M, Moore JP.

AIDS Res Hum Retroviruses. 2000 Feb 10;16(3):259-71.

PMID:
10710214

Supplemental Content

Loading ...
Support Center